Recently, the study by Sangsuwannukul et al125 demonstrated promising results indicating the efficacy of the fourth‐generation anti‐CD133‐CAR‐T‐cells in eliminating the CD133‐expressing cholangiocarcinoma stem cells dose‐dependently. Here, PROM1 is linked to cholangiocarcinoma.